Which has grown faster, BBIO or CORT?

Over the past five years, BBIO grew revenue faster — BBIO at a 62.61% CAGR versus CORT at 19.35%.

Is BBIO or CORT more profitable?

CORT runs the higher net margin — BBIO at -97.64% versus CORT at 6.61%.

How have BBIO and CORT total returns compared?

Over the past 5 years, BBIO delivered 7.38% and CORT delivered 43.90% annualized total return. Past performance doesn't predict future results.

BridgeBio Pharma, Inc. (BBIO) vs Corcept Therapeutics Incorporated (CORT)

A side-by-side comparison of BridgeBio Pharma, Inc. and Corcept Therapeutics Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BBIO

BridgeBio Pharma, Inc.

$12.95B

$66.14HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

CORT

Corcept Therapeutics Incorporated

$13.19B

$122.03HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — BBIO vs CORT

growth of $100 · dividends reinvested · last 7y

BBIO +140.1% (+13.3%/yr)CORT +1056.7% (+41.9%/yr)CORT compounded faster over this window

BBIO CORT

BBIO vs CORT: by the numbers

•CORT is the larger company ($13.19B vs $12.95B market cap).
•CORT is profitable (6.61% net margin) while BBIO runs a net loss (-97.64%).
•BBIO grew revenue faster over the past five years (62.61% vs 19.35% CAGR).

Metrics side by side

Valuation

Metric	BBIO	CORT
P/E ratio	N/A	290.55
P/S ratio	18.17	15.88
P/B ratio	N/A	18.69
EV / EBITDA	N/A	1483.24
FCF yield	N/A	0.81%

Profitability

Metric	BBIO	CORT
Gross margin	93.35%	98.30%
Operating margin	-113.35%	0.77%
Net margin	-97.64%	6.61%
ROE	N/A	7.78%
ROIC	-62.14%	0.87%

Growth (annualized)

Metric	BBIO	CORT
Revenue CAGR (5Y)	62.61%	19.35%
EPS CAGR (5Y)	N/A	0.64%
FCF CAGR (5Y)	N/A	-4.40%
Total return CAGR (5Y)	7.38%	43.90%

Frequently asked

Which has grown faster, BBIO or CORT?: Over the past five years, BBIO grew revenue faster — BBIO at a 62.61% CAGR versus CORT at 19.35%.
Is BBIO or CORT more profitable?: CORT runs the higher net margin — BBIO at -97.64% versus CORT at 6.61%.
How have BBIO and CORT total returns compared?: Over the past 5 years, BBIO delivered 7.38% and CORT delivered 43.90% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BBIO analysis Full CORT analysis Interactive comparison tool

Dig into the metrics

Corcept Therapeutics P/E ratio BridgeBio Pharma ROE Corcept Therapeutics ROE BridgeBio Pharma operating margin Corcept Therapeutics operating margin BridgeBio Pharma revenue growth Corcept Therapeutics revenue growth BridgeBio Pharma free cash flow Corcept Therapeutics free cash flow

BridgeBio Pharma & Corcept Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.